Skip to main content

Table 1 Network-meta analysis estimates of entire period treatment duration for VTE patients

From: Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials

 

Odds ratio (95% Confidence Interval) for outcome of major bleeding

Odds ratio (95% Confidence Interval) for outcome of VTE recurrence

A (3 months)

2.05 (0.75, 5.66)

2.03 (0.28, 14.58)

3.25 (0.76, 13.91)

1.03 (0.69, 1.53)

B (6 months)

0.99 (0.11, 9.07)

1.58 (0.49, 5.07)

0.82 (0.43, 1.55)

0.80 (0.38, 1.68)

C (12 months)

1.60 (0.14, 18.43)

0.41 (0.20, 0.84)a

0.40 (0.22, 0.73)a

0.51 (0.19, 1.31)

D (≥24 months)

  1. The entire period results from network meta-analysis are presented as odds ratio (95% Confidence Intervals) between the column-defining and row-defining treatment duration. Odds ratio for comparisons are in the cell in common between the column-defining and row-defining treatment. For outcome of VTE recurrence, row treatment is compared with column treatment (ie, column treatment is reference). For outcome of major bleeding, column treatment is compared with row treatment (ie, row treatment is reference). Numbers in brackets indicate 95% Confidence Intervals. Numbers in bold represent statistically significant results. Data in bold represents the primary efficacy outcome (VTE recurrence) and the rest represents the primary safety outcome (major bleeding)
  2. VTE venous thromboembolism
  3. A-D: Treatment duration
  4. a Statistically significant results